Sequoia Financial Group (ASX:SEQ) FY21 guidance
23 Apr 2021 - Sequoia Financial Group Limited (ASX:SEQ) Managing Director Garry Crole discusses the company's FY21 profit update and guidance.
23Apr
23Apr
Capral (ASX:CAA) FY20 results & outlook
23 Apr 2021 - Capral Limited (ASX:CAA) Managing Director Tony Dragicevich talks about the company's strong FY20 results despite COVID, its product mix, operating environment and outlook.
16Apr
Novatti Group (ASX:NOV) discusses growth opportunities in the payments sector
16 Apr 2021 - Novatti Group Limited (ASX:NOV) CEO Peter Cook talks about the growing demand for digital payments and the opportunities this presents for the company.
06Apr
LaserBond (ASX:LBL) specialist surface engineering
06 Apr 2021 - LaserBond Limited (ASX:LBL) CEO Wayne Hooper talks about the company's strong 1H21 results despite the impact of COVID-19, its focus on growth opportunities to expand its national footprint, and business strategy, including potential growth via acquisitions.
31Mar
Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) developing new classes of synthetic anti-infectives
31 Mar 2021 - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q) CEO and Managing Director James Graham talks about progress with the company's lead anti-infective candidate Recce 327, its expanding portfolio of synthetic anti-infectives targeting viral pathogens and a broad range of bacteria, clinical trial results and priorities for 2021.
29Mar
Immutep (ASX:IMM) LAG-3 validated in Bristol Myers Squibb trial
29 Mar 2021 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt talks about the Bristol Myers Squibb trial evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in patients with previously untreated metastatic or unresectable melanoma, meeting its primary endpoint of progression-free survival and what it means for Immutep.
29Mar
XTEK (ASX:XTE) 1H21 results & outlook
29 Mar 2021 - XTEK Limited (ASX:XTE) Managing Director Phillipe Odouard talks 1H21 results, discussing the company's expanded operational capacity to meet demand for its high-value proprietary solutions in a favourable market environment for domestic and global defence industries.
29Mar
Telix Pharmaceuticals (ASX:TLX) – harnessing radiation to see and treat a range of oncology targets
29 Mar 2021 - Telix Pharmaceuticals Limited (ASX:TLX) Chief Business Officer Dr David Cade talks about the company's clinical programs, including approvals, partnerships and significant value events anticipated in 2021.
29Mar
Telix Pharmaceuticals (ASX:TLX) – harnessing radiation to see and treat a range of oncology targets
29 Mar 2021 - Telix Pharmaceuticals Limited (ASX:TLX) Chief Business Officer Dr David Cade talks about the company's clinical programs, including approvals, partnerships and significant value events anticipated in 2021.
24Mar
Market update with Shaw and Partners, March 2021
24 Mar 2021 - Shaw and Partners Chief Investment Officer Martin Crabb discusses historical precedence for recovering from government spending, the possible rise of interest rates, labour market data, and investment strategies in this environment.